C4 Therapeutics Announces the Addition of Ryan B. Corcoran, M.D., Ph.D. to the Scientific Advisory Board (SAB)

WATERTOWN, Mass. – C4 Therapeutics (C4T) today announced the appointment of Ryan B. Corcoran, M.D., Ph.D., to the Company’s Scientific Advisory Board (SAB). “C4 Therapeutics has established a scientific advisory board of leading researchers and physicians and are excited to expand that expertise with the addition of Ryan Corcoran, a world leader in oncogenic signaling pathways,” said Andy…

C4 Therapeutics Announces Transformation of Strategic Collaboration to Discover and Develop Degrader-based Medicines with Roche

WATERTOWN, Mass. – C4 Therapeutics (C4T) today announced the transformation of its ongoing research and development partnership with Roche focusing on new cancer treatments based on C4T’s targeted protein degradation technology. “We are excited to see our partnership with Roche evolve and further accelerate our efforts to bring degrader-based medicines into the clinic,” said Andrew…

Biogen and C4 Therapeutics Enter into Strategic Collaboration to Discover and Develop Potential New Treatments for Neurological Conditions

C4T’s targeted protein degradation platform provides a novel approach to neuroscience drug discovery and development, complementing Biogen’s broader research and development efforts across multiple modalities CAMBRIDGE and WATERTOWN, Mass. – Biogen Inc (Nasdaq: BIIB) and C4 Therapeutics (C4T) announced today that they have entered into a strategic collaboration to investigate the use of C4T’s novel protein degradation…